Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Instil Bio Inc (TIL)

Instil Bio Inc (TIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,499
  • Shares Outstanding, K 6,526
  • Annual Sales, $ 0 K
  • Annual Income, $ -156,090 K
  • EBIT $ -75 M
  • EBITDA $ -70 M
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -2.27
  • Number of Estimates 2
  • High Estimate -0.89
  • Low Estimate -3.65
  • Prior Year -1.99
  • Growth Rate Est. (year over year) -14.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.01 +8.40%
on 12/19/24
30.64 -32.73%
on 12/06/24
-2.75 (-11.77%)
since 11/20/24
3-Month
19.01 +8.40%
on 12/19/24
72.87 -71.72%
on 09/24/24
-45.64 (-68.89%)
since 09/20/24
52-Week
6.72 +206.70%
on 12/21/23
92.00 -77.60%
on 09/13/24
+13.66 (+196.55%)
since 12/20/23

Most Recent Stories

More News
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TIL : 20.61 (+2.64%)
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?

This drugmaker's lead candidate could become a top-selling cancer therapy.

TIL : 20.61 (+2.64%)
SMMT : 17.87 (-2.88%)
BNTX : 113.08 (+1.56%)
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Although death rates for some cancers are declining, the world is facing a sharp increase in cancer...

ONCY : 0.8310 (-6.36%)
ZNTL : 3.00 (+2.39%)
TIL : 20.61 (+2.64%)
IMRX : 2.00 (+8.70%)
ZLAB : 26.72 (+1.91%)
ONC.TO : 1.19 (-9.16%)
2 Stocks Up Over 700% in 2024 That Could Soar Even Further

These relatively small companies are developing new cancer therapies that could generate billions in annual sales.

TIL : 20.61 (+2.64%)
SMMT : 17.87 (-2.88%)
Here's Why Everyone's Talking About Summit Therapeutics

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

SMMT : 17.87 (-2.88%)
TIL : 20.61 (+2.64%)
BNTX : 113.08 (+1.56%)
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.

TIL : 20.61 (+2.64%)
SMMT : 17.87 (-2.88%)
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The investigations concern...

TIL : 20.61 (+2.64%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are...

TIL : 20.61 (+2.64%)
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) on behalf...

TIL : 20.61 (+2.64%)
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Instil Bio, Inc. (“Instil Bio” or the “Company”)...

TIL : 20.61 (+2.64%)

Business Summary

Instil Bio Inc. is a clinical-stage biopharmaceutical company. It is focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer. Instil Bio Inc. is based in DALLAS.

See More

Key Turning Points

3rd Resistance Point 24.75
2nd Resistance Point 23.32
1st Resistance Point 21.97
Last Price 20.61
1st Support Level 19.19
2nd Support Level 17.76
3rd Support Level 16.41

See More

52-Week High 92.00
Fibonacci 61.8% 59.42
Fibonacci 50% 49.36
Fibonacci 38.2% 39.30
Last Price 20.61
52-Week Low 6.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar